---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-001628"
form_type: "8-K"
ticker: "TWST"
cik: "0001581280"
company_name: "Twist Bioscience Corp"
filed_at: "2024-01-05T23:59:59+00:00"
generated_at: "2026-06-07T03:06:18.337447+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Twist Bioscience appoints Adam Laponis as CFO effective January 8, 2024

## Summary
- Adam Laponis named CFO, effective Jan 8, 2024; succeeded James Thorburn.
- Annual base salary of $450,000; signing bonus $195,000 with clawback if terminated for cause within one year.
- Target annual incentive for 2024 at 55% of base salary; equity grant includes 50,000 RSUs (4-yr vest, 1-yr cliff) plus 70,000 shares under exec comp programs.
- Laponis previously CFO at Eargo, VP at Tesla, VP/CFO at Cardinal Health, and held roles at Johnson & Johnson.
- No family relationships or related-party transactions with Laponis; disclosure via prior 8-K for Thorburn’s departure.

## SEC filing metadata
- accession: 0001104659-24-001628
- form_type: 8-K
- ticker: TWST
- cik: 0001581280
- company_name: Twist Bioscience Corp
- filed_at: 2024-01-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1581280/000110465924001628/0001104659-24-001628-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1581280/000110465924001628/tm2333797d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-001628
- JSON: https://secwatch.observer/filing/0001104659-24-001628.json
- Plain text: https://secwatch.observer/filing/0001104659-24-001628.txt

## Key facts
- Executive change
  Adam Laponis was appointed as Chief Financial Officer at Twist Bioscience Corp.
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On January 5, 2024, Twist Bioscience Corporation (the “Company”) announced the appointment of Adam Laponis as the Company’s Chief Financial Officer and principal financial officer, effective January 8, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1581280/000110465924001628/0001104659-24-001628-index.htm
- Executive change
  James Thorburn departed as Chief Financial Officer at Twist Bioscience Corp.
  - Action: will no longer serve
  - Role: Chief Financial Officer
  source text: As previously reported by the Company in its Form 8-K filed on August 4, 2023 (the “Prior 8-K”), upon commencement of employment by Mr. Laponis, James Thorburn will no longer serve as the Company’s Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1581280/000110465924001628/0001104659-24-001628-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.